Functional imaging of lung cancer using dual energy CT: How does iodine related attenuation correlate with standardized uptake value of 18FDG-PET-CT?

European Radiology

Volumn 22, Issue 1, 2012, Pages 93-103

  Schmid Bindert, G ^a   Henzler, Thomas ^a   Chu, T Q ^a   Meyer, M ^a   Nance Jr , J W ^a,b   Schoepf, U J ^a,b   Dinter, D J ^a   Apfaltrer, P ^a   Krissak, R ^a   Manegold, C ^a   Schoenberg, S O ^a   Fink, C ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

18FDG PET CT; Dual energy computed tomography; Lung cancer; Tumor vascularity; Tumour staging

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IODINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DUAL ENERGY COMPUTED TOMOGRAPHY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LYMPH NODE; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IODINE; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; SMALL CELL LUNG CARCINOMA;

EID: 84857059498     PISSN: 09387994     EISSN: 14321084     Source Type: Journal    
DOI: 10.1007/s00330-011-2230-3     Document Type: Article

References (36)

1. Berghmans T, Dusart M, Paesmans M, Hossein-Foucher C, Buvat I, Castaigne C, Scherpereel A, Mascaux C, Moreau M, Roelandts M, Alard S, Meert AP, Patz EF Jr, Lafitte JJ, Sculier JP (2008) Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. J Thorac Oncol 3:6-12
2. De Wever W, Ceyssens S, Mortelmans L, Stroobants S, Marchal G, Bogaert J, Verschakelen JA (2007) Additional value of PET-CT in the staging of lung cancer: comparison with CT alone, PET alone and visual correlation of PET and CT. Eur Radiol 17:23-32 (Pubitemid 46063025)
3. Orlacchio A, Schillaci O, Antonelli L, D'Urso S, Sergiacomi G, Nicoli P, Simonetti G (2007) Solitary pulmonary nodules: morphological and metabolic characterisation by FDG-PET-MDCT. Radiol Med 112:157-173 (Pubitemid 46474823)
4. Higashi K, Matsunari I, Ueda Y, Ikeda R, Guo J, Oguchi M, Tonami H, Yamamoto I (2003) Value of whole-body FDG PET in management of lung cancer. Ann Nucl Med 17:1-14 (Pubitemid 36417568)
5. Eschmann SM, Friedel G, Paulsen F, Reimold M, Hehr T, Budach W, Scheiderbauer J, Machulla HJ, Dittmann H, Vonthein R, Bares R (2006) Is standardised (18)F-FDG uptake value an outcome predictor in patients with stage III non-small cell lung cancer? Eur J Nucl Med Mol Imaging 33:263-269
6. Higashi K, Ueda Y, Arisaka Y, Sakuma T, Nambu Y, OguchiM, Seki H, Taki S, Tonami H, Yamamoto I (2002) 18 F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer. J Nucl Med 43:39-45 (Pubitemid 34101186)
7. Jeong HJ, Chung JK, Kim YK, Kim CY, Kim DG, Jeong JM, Lee DS, Jung HW, Lee MC (2002) Usefulness of whole-body (18)FFDG PET in patients with suspected metastatic brain tumors. J Nucl Med 43:1432-1437 (Pubitemid 35285866)
8. Pandit N, Gonen M, Krug L, Larson SM (2003) Prognostic value of [18 F]FDG-PET imaging in small cell lung cancer. Eur J Nucl Med Mol Imaging 30:78-84 (Pubitemid 36692896)
9. Vansteenkiste JF, Mortelmans LA (1999) FDG-PETin the locoregional lymph node staging of non-small cell lung cancer. A comprehensive review of the leuven lung cancer group experience. Clin Positron Imaging 2:223-231
10. Downey RJ, Akhurst T, Gonen M, Vincent A, Bains MS, Larson S, Rusch V (2004) Preoperative F-18 fluorodeoxyglucosepositron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. J Clin Oncol 22:3255-3260 (Pubitemid 41103680)
11. Miles KA, Griffiths MR, Fuentes MA (2001) Standardized perfusion value: universal CT contrast enhancement scale that correlates with FDG PET in lung nodules. Radiology 220:548-553 (Pubitemid 32667201)
12. Johnson TR, Krauss B, Sedlmair M, Grasruck M, Bruder H, Morhard D, Fink C, Weckbach S, Lenhard M, Schmidt B, Flohr T, Reiser MF, Becker CR (2007) Material differentiation by dual energy CT: initial experience. Eur Radiol 17:1510-1517 (Pubitemid 46767599)
13. Pansini V, Remy-Jardin M, Faivre JB, Schmidt B, Dejardin-Bothelo A, Perez T, Delannoy V, Duhamel A, Remy J (2009) Assessment of lobar perfusion in smokers according to the presence and severity of emphysema: preliminary experience with dual-energy CTangiography. Eur Radiol 19:2834-2843
14. Chae EJ, Song JW, Seo JB, Krauss B, Jang YM, Song KS (2008) Clinical utility of dual-energy CT in the evaluation of solitary pulmonary nodules: initial experience. Radiology 249:671-681
15. Shanbhogue AK, Karnad AB, Prasad SR (2010) Tumor response evaluation in oncology: current update. J Comput Assist Tomogr 34:479-484
16. Schaefer JF, Schneider V, Vollmar J, Wehrmann M, Aebert H, Friedel G, Vonthein R, Schick F, Claussen CD (2006) Solitary pulmonary nodules: association between signal characteristics in dynamic contrast enhanced MRI and tumor angiogenesis. Lung Cancer 53:39-49 (Pubitemid 43831358)
17. Schaefer JF, Vollmar J, Schick F, Vonthein R, Seemann MD, Aebert H, Dierkesmann R, Friedel G, Claussen CD (2004) Solitary pulmonary nodules: dynamic contrast-enhanced MR imaging-perfusion differences in malignant and benign lesions. Radiology 232:544-553 (Pubitemid 38971298)
18. Hellwig D, Graeter TP, Ukena D, Groeschel A, Sybrecht GW, Schaefers HJ, Kirsch CM (2007) 18 F-FDG PET for mediastinal staging of lung cancer: which SUV threshold makes sense? J Nucl Med 48:1761-1766 (Pubitemid 350099319)
19. Miles KA, Griffiths MR, Keith CJ (2006) Blood flow-metabolic relationships are dependent on tumour size in non-small cell lung cancer: a study using quantitative contrast-enhanced computer tomography and positron emission tomography. Eur J Nucl Med Mol Imaging 33:22-28 (Pubitemid 41785305)
20. Kieser A, Weich HA, Brandner G, Marme D, Kolch W (1994) Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene 9:963-969 (Pubitemid 24065938)
21. Mathupala SP, Rempel A, Pedersen PL (1997) Aberrant glycolytic metabolism of cancer cells: a remarkable coordination of genetic, transcriptional, post-translational, and mutational events that lead to a critical role for type II hexokinase. J Bioenerg Biomembr 29:339-343
22. Yi CA, Lee KS, Kim EA, Han J, Kim H, Kwon OJ, Jeong YJ, Kim S (2004) Solitary pulmonary nodules: dynamic enhanced multi-detector row CT study and comparison with vascular endothelial growth factor and microvessel density. Radiology 233:191-199 (Pubitemid 39280974)
23. Charnley N, Donaldson S, Price P (2009) Imaging angiogenesis. Methods Mol Biol 467:25-51
24. Swensen SJ (2000) Functional CT: lung nodule evaluation. Radiographics 20:1178-1181
25. Swensen SJ, Brown LR, Colby TV, Weaver AL (1995) Pulmonary nodules: CT evaluation of enhancement with iodinated contrast material. Radiology 194:393-398
26. Swensen SJ, Morin RL, Schueler BA, Brown LR, Cortese DA, Pairolero PC, Brutinel WM (1992) Solitary pulmonary nodule: CT evaluation of enhancement with iodinated contrast material-a preliminary report. Radiology 182:343-347
27. Yamashita K, Matsunobe S, Tsuda T, Nemoto T, Matsumoto K, Miki H, Konishi J (1995) Solitary pulmonary nodule: preliminary study of evaluation with incremental dynamic CT. Radiology 194:399-405
28. Zhang M, Kono M (1997) Solitary pulmonary nodules: evaluation of blood flow patterns with dynamic CT. Radiology 205:471-478 (Pubitemid 27467328)
29. Tateishi U, Kusumoto M, Nishihara H, Nagashima K, Morikawa T, Moriyama N (2002) Contrast-enhanced dynamic computed tomography for the evaluation of tumor angiogenesis in patients with lung carcinoma. Cancer 95:835-842 (Pubitemid 34839676)
30. Aukema TS, Kappers I, Olmos RA, Codrington HE, van Tinteren H, van Pel R, Klomp HM (2010) Is 18 F-FDG PET/CT useful for the early prediction of histopathologic response to neoadjuvant erlotinib in patients with non-small cell lung cancer? J Nucl Med 51:1344-1348
31. Kaira K, Oriuchi N, Shimizu K, Ishikita T, Higuchi T, Imai H, Yanagitani N, Sunaga N, Hisada T, Ishizuka T, Kanai Y, Endou H, Nakajima T, Endo K, Mori M (2009) Correlation of angiogenesis with 18 F-FMT and 18 F-FDG uptake in non-small cell lung cancer. Cancer Sci 100:753-758
32. de Langen AJ, van den Boogaart V, Lubberink M, Backes WH, Marcus JT, van Tinteren H, Pruim J, Brans B, Leffers P, Dingemans AM, Smit EF, Groen HJ, Hoekstra OS (2010) Monitoring response to antiangiogenic therapy in non-small cell lung cancer using imaging markers derived from PET and dynamic contrast-enhanced MRI. J Nucl Med 52:48-55
33. Lind JS, Meijerink MR, Dingemans AM, van Kuijk C, Ollers MC, de Ruysscher D, Postmus PE, Smit EF (2010) Dynamic contrastenhanced CT in patients treated with sorafenib and erlotinib for non-small cell lung cancer: a new method of monitoring treatment? Eur Radiol 20:2890-2898
34. Ryu JS, Choi NC, Fischman AJ, Lynch TJ, Mathisen DJ (2002) FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: correlation with histopathology. Lung Cancer 35:179-187 (Pubitemid 34136096)
35. De Leyn P, Lardinois D, Van Schil PE, Rami-Porta R, Passlick B, Zielinski M, Waller DA, Lerut T, Weder W (2007) ESTS guidelines for preoperative lymph node staging for non-small cell lung cancer. Eur J Cardiothorac Surg 32:1-8 (Pubitemid 46874948)
36. Huang YE, Chen CF, Huang YJ, Konda SD, Appelbaum DE, Pu Y (2010) Interobserver variability among measurements of the maximum and mean standardized uptake values on (18)F-FDG PET/CT and measurements of tumor size on diagnostic CT in patients with pulmonary tumors. Acta Radiol 51:782-788